Samuel A Stoner
Overview
Explore the profile of Samuel A Stoner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
357
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yan M, Liu M, Davis A, Stoner S, Zhang D
Leukemia
. 2023 Oct;
38(1):31-44.
PMID: 37838757
T(8;21)(q22;q22), which generates the AML1-ETO fusion oncoprotein, is a common chromosomal abnormality in acute myeloid leukemia (AML) patients. Despite having favorable prognosis, 40% of patients will relapse, highlighting the need...
2.
Arimoto K, Miyauchi S, Troutman T, Zhang Y, Liu M, Stoner S, et al.
Nat Commun
. 2023 Jan;
14(1):251.
PMID: 36646704
While immunotherapy has emerged as a breakthrough cancer therapy, it is only effective in some patients, indicating the need of alternative therapeutic strategies. Induction of cancer immunogenic cell death (ICD)...
3.
Davis A, Johnson D, Zheng D, Wang R, Jayne N, Liu M, et al.
Blood
. 2021 Sep;
139(3):424-438.
PMID: 34482400
Posttranscriptional regulation has emerged as a driver for leukemia development and an avenue for therapeutic targeting. Among posttranscriptional processes, alternative polyadenylation (APA) is globally dysregulated across cancer types. However, limited...
4.
Stoner S, Liu K, Andrews E, Liu M, Arimoto K, Yan M, et al.
Blood Cancer J
. 2020 Feb;
10(2):16.
PMID: 32029705
Large-scale chromosomal translocations are frequent oncogenic drivers in acute myeloid leukemia (AML). These translocations often occur in critical transcriptional/epigenetic regulators and contribute to malignant cell growth through alteration of normal...
5.
Stoner S, Yan M, Liu K, Arimoto K, Shima T, Wang H, et al.
Blood
. 2019 Aug;
134(20):1730-1744.
PMID: 31434702
Heterozygous deletions within chromosome 20q, or del(20q), are frequent cytogenetic abnormalities detected in hematologic malignancies. To date, identification of genes in the del(20q) common deleted region that contribute to disease...
6.
Arimoto K, Miyauchi S, Stoner S, Fan J, Zhang D
J Leukoc Biol
. 2018 Jan;
PMID: 29357192
Type I IFNs (α, β, and others) are a family of cytokines that are produced in physiological conditions as well as in response to the activation of pattern recognition receptors. ...
7.
Arimoto K, Lochte S, Stoner S, Burkart C, Zhang Y, Miyauchi S, et al.
Nat Struct Mol Biol
. 2017 Feb;
24(3):279-289.
PMID: 28165510
Type I interferons (IFNs) are multifunctional cytokines that regulate immune responses and cellular functions but also can have detrimental effects on human health. A tight regulatory network therefore controls IFN...
8.
Weng S, Stoner S, Zhang D
Oncotarget
. 2016 Sep;
7(44):72356-72372.
PMID: 27655702
Cytogenetic aberrations, such as chromosomal translocations, aneuploidy, and amplifications, are frequently detected in hematological malignancies. For many of the common autosomal aberrations, the mechanisms underlying their roles in cancer development...
9.
Stoner S, Duggan E, Condello D, Guerrero A, Turk J, Narayanan P, et al.
Cytometry A
. 2015 Oct;
89(2):196-206.
PMID: 26484737
Extracellular vesicles (EVs) are attracting attention as vehicles for inter-cellular signaling that may have value as diagnostic or therapeutic targets. EVs are released by many cell types and by different...
10.
Nolan J, Stoner S
Cytometry A
. 2013 Jan;
83(3):301-5.
PMID: 23335161
The analysis of individual nanoparticles by flow cytometry involves the measurement of dim signals that are near the detection limits of the instrument. Discriminating the signal from particles of interest...